Livagen
One of the Khavinson "bioregulator" peptides from Russian aging research. Evidence comes mainly from Russian cell and animal studies.
Sold as a supplement in Russia; not approved in the US. Research use only.
Look it up on Wikipedia18 listings across 16 independently tested vendors, ranked by price per milligram after coupon codes anyone can use. Vendors you can only order from by message are hidden.
Not an FDA-approved drug and not nominated for FDA's 503A bulks list, so US pharmacies can't legally compound it.
Daily price tracking started October 7, 2026; a price-history chart appears here once a few days have been collected.
| Vendor | Trust | Listing | Vials | Price | Per mg | |
|---|---|---|---|---|---|---|
Andy Peps Studio #64 by metascore · China |
LI20 Livagen 20mg * 10 vials | 10 × 20 mg = 200 mg | $95.00 $9.50 per vial |
$0.475 | Buy | |
Baohua Dongnuo Biotechnology BHD #77 by metascore · China |
LI20 Livagen 20mg * 10 vials | 10 × 20 mg = 200 mg | $95.00 $9.50 per vial |
$0.475 | Buy | |
LN Peptides #254 by metascore · China |
Metascore 71Finnrick 72%Bought vials 99% of label · 39 testsTitrateLabNo report for thisOnline checkout |
LI20 Livagen 20mg * 10 vials | 10 × 20 mg = 200 mg | $95.00 $9.50 per vial |
$0.475 | Buy |
BeiBangAn #28 by metascore · China |
LI20 Livagen 20mg * 10 vials | 10 × 20 mg = 200 mg | $95.00 $9.50 per vial |
$0.475 | Buy | |
Uther #62 by metascore · China |
Metascore 79Finnrick 64%Bought vials 105% of label · 73 testsTitrateLabNo report for thisOnline checkout |
Livagen 20mg (10 Vials / Kit) | 10 × 20 mg = 200 mg | $150.00 $15.00 per vial |
$0.750 | Buy |
Qingdao Sigma Chemical QSC #69 by metascore |
Livagen 20mg | 20-Vial Kit | Liver & Immune System Bioregulator | 20 × 20 mg = 400 mg | $470.00 $23.50 per vial |
$1.18 | Buy | |
Bulk Peptide Wholesale #29 by metascore |
Metascore 82 medium confidenceFinnrick 68%Bought vials 103% of label · 7 testsTitrateLab · PeptideBaseNo report for thisOnline checkout |
Livagen 20 mg (10 vials) | 10 × 20 mg = 200 mg | $250.00 $25.00 per vial |
$1.25 | Buy |
Qingdao Sigma Chemical QSC #69 by metascore |
Livagen 20mg | 10-Vial Kit | Liver & Immune System Bioregulator | 10 × 20 mg = 200 mg | $260.00 $26.00 per vial |
$1.30 | Buy | |
Peptidology #5 by metascore · US, AZ 85254 |
Metascore 87Finnrick 71%Bought vials 97% of label · 18 testsTitrateLab · PeptideBase · Peptide Critic · PeptideCheckedNo report for thisConfirmed with lab: 34 of 34Online checkout |
Livagen 20 mg (20mg) | 1 × 20 mg | $44.00 | $2.20 | Buy |
Go Alpha Labs Peptides #51 by metascore · US |
Metascore 80Finnrick 52%Bought vials 100% of label · 11 testsTitrateLabNo report for thisConfirmed with lab: 37 of 37Online checkout |
Livagen (20mg) (10 Vials) | 10 × 20 mg = 200 mg | $489.99 $49.00 per vial |
$2.45 | Buy |
Amino Usa #136 by metascore · US |
Metascore 74 medium confidenceFinnrick 32%Bought vials 89% of label · 3 testsTitrateLabLab 99.8% pure · 104% of labelAccount needed |
Livagen 20mg | 1 × 20 mg | $50.00 | $2.50 | Buy |
Eros Peptides #129 by metascore · US, GA 30339 |
Metascore 74 medium confidenceFinnrick 77%Bought vials 110% of label · 3 testsTitrateLab · Peptide CriticLab report (image)Online checkout |
Livagen 20MG | 1 × 20 mg | $50.99 | $2.55 | Buy |
Go Alpha Labs Peptides #51 by metascore · US |
Metascore 80Finnrick 52%Bought vials 100% of label · 11 testsTitrateLabNo report for thisConfirmed with lab: 37 of 37Online checkout |
Livagen (20mg) | 1 × 20 mg | $59.99 | $3.00 | Buy |
Amino Asylum #245 by metascore |
Metascore 71Finnrick 62%PepIndex 26/100Bought vials 100% of label · 15 testsTitrateLab · PeptideBaseNo report for thisOnline checkout |
Livagen 20MG | 1 × 20 mg | $64.99 | $3.25 | Buy |
Skye Peptides #72 by metascore · US: CA |
Metascore 78Finnrick 57%Bought vials 114% of label · 92 testsTitrateLabNo report for thisConfirmed with lab: 25 of 25Account needed |
Livagen 20 mg | 1 × 20 mg | $69.00 | $3.45 | Buy |
Dragon Pharma #42 by metascore |
Livagen (vial) [U.S. Domestic] | 1 × 20 mg | $69.00 | $3.45 | Buy | |
Core Peptides #282 by metascore |
Metascore 70 medium confidenceFinnrick 76%PepIndex 24/100Bought vials 92% of label · 4 testsTitrateLab · PeptideBase · Peptide Critic · PeptideCheckedLab 99% pureOnline checkout |
Livagen – 20MG | 1 × 20 mg | $73.00 | $3.65 | Buy |
Biolongevity Labs #166 by metascore · US, Akron, OH 44321 |
Metascore 73Finnrick 71%PepIndex 58/100Bought vials 102% of label · 34 testsTitrateLab · Peptide CriticNo report for thisOnline checkout |
Livagen Peptide (20mg) | 1 × 20 mg | $79.97 | $4.00 | Buy |
Mixing a 20 mg vial
What each common amount of bacteriostatic water gives you on a U-100 insulin syringe. Pick a vial size above to change it.
| Water | Strength | Per 10 units (0.1 mL) | Per unit |
|---|---|---|---|
| 1 mL | 20 mg/mL | 2,000 mcg | 200 mcg |
| 2 mL | 10 mg/mL | 1,000 mcg | 100 mcg |
| 3 mL | 6.667 mg/mL | 666.7 mcg | 66.67 mcg |
| 5 mL | 4 mg/mL | 400 mcg | 40 mcg |
Published lab results
3 certificates of analysis that vendors publish for Livagen. Numbers are only filled in where the document is readable text; image-only COAs are linked without numbers. A vendor's own COA shows one tested sample, not every batch.
| Vendor | Lab | Date | Label | Measured | Purity | Batch | |
|---|---|---|---|---|---|---|---|
Core Peptides |
Vanguard Laboratory | 2026-07-22 | 20 mg | – | 99.05% | C74144 | View |
Amino Usa |
BioRegen | 2026-07-06 | 20 mg | 20.8 mg 104% | 99.76% | 26LIV20-0004 | View |
Eros PeptidesCOA note |
Janoshik | – | 20 mg | – | – | View (image) |
Doses studied in research Animal or lab studies only
What was given to people (or animals) in published studies and official labels, each linked to its source. This is not a recommendation: study products, purity and supervision differ from research-grade vials.
Animal studies: Studies used cultured lymphocytes from elderly people, rat liver and pancreas tissue cultures, and rats given Livagen by mouth for two weeks; none of the abstracts state the concentration or mg/kg dose.
Not an approved drug, and no study has given Livagen to people. Results in cultured cells and rats do not translate directly to doses in people.
What the research says
Livagen (the tetrapeptide Lys-Glu-Asp-Ala) has been studied mainly by Russian and Georgian groups in cultured lymphocytes from elderly people and patients, where it decondenses chromatin and reactivates ribosomal genes, plus some rat liver and enzyme work. These are laboratory measurements on cells rather than clinical trials, and no study reports a health outcome in people.
Key papers ✓ 8~ 2? 2
-
Effects of Livagen peptide on chromatin activation in lymphocytes from old people.Cells / labIn vitro chromatin study
In cultured lymphocytes from old people, Livagen activated ribosomal genes and decondensed pericentromeric heterochromatin, a chromatin-level change with no clinical endpoint measured.
Study details
- Studied
- Cultured lymphocytes from old people
- Main outcome
- Ribosomal gene activity, heterochromatin parameters
- Authors' conclusion
- Livagen induced activation of ribosomal genes and decondensation of heterochromatin, i.e. de-heterochromatinization (activation) of chromatin in lymphocytes from old people.
- Limitations
- In vitro cell study; sample size not stated in abstract.
-
Effects of short peptides on lymphocyte chromatin in senile subjects.Cells / labIn vitro study of five short peptides (Vilon, Epithalon, Livagen, Prostamax, Cortagen) on chromatin
In leukocytes from subjects aged 75-88, Livagen and four related peptides activated ribosome genes and decondensed tightly packed chromatin.
Study details
- Studied
- Leukocytes from subjects aged 75-88 years
- Compared with
- Untreated cells
- Main outcome
- Ribosome gene activity and chromatin condensation
- Sample
- Number of subjects not stated; leukocytes from subjects aged 75-88
- Authors' conclusion
- All peptides activated ribosome genes and decondensed chromatin; Epithalon, Livagen and Prostamax decondensed chromosome 1 pericentromeric chromatin.
- Limitations
- In vitro; not specific to Prostamax; no clinical outcome.
-
Anti-aging peptide bioregulators induce reactivation of chromatin.Cells / labIn vitro study of Epitalon, Livagen and Vilon
In lymphocytes from people aged 75-88, Livagen (with epitalon and vilon) reactivated ribosomal genes and unwound total heterochromatin.
Study details
- Studied
- Cultured lymphocytes from old (75-88 yr) people
- Main outcome
- Structural and facultative heterochromatin
- Authors' conclusion
- Epitalon, Livagen and Vilon reactivated ribosomal genes and deheterochromatinized chromatin; Epitalon and Livagen (not Vilon) decondensed pericentromeric heterochromatin of chromosomes 1 and 9.
- Limitations
- In vitro cell study; sample size not stated in abstract.
-
Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals.Cells / labIn vitro study of CoCl2 and Livagen, alone and combined
In cultured lymphocytes from 80-91-year-olds, Livagen induced chromatin decondensation and modified cobalt-chloride-related chromosome changes.
Key resultLivagen decreased CoCl2-induced changes by 3.4 +/- 0.6% (control group 4.2 +/- 0.7%); CoCl2 raised chromosomal aberrations in old donors (P < 0.05)
Study details
- Studied
- Cultured lymphocytes from 80- to 91-year-old donors and 18- to 30-year-old controls
- Compared with
- Young control group
- Main outcome
- Total heterochromatin, chromosome instability, sister chromatid exchanges
- Authors' conclusion
- Livagen could reactivate (deheterochromatinize) chromatin in lymphocytes of aged individuals; Co2+ ions and Livagen target different chromosomal regions.
- Limitations
- In vitro cell study; donor numbers not stated in abstract.
-
[EVALUATION OF GENOMIC PARAMETERS IN DUCTAL BREAST CANCER PATIENTS AND THE ABILITY OF IT'S CORRECTION].Cells / labIn vitro study of DNA damage, chromosomal abnormalities and SCEs with Livagen and cobalt ions
In lymphocyte cultures from ductal breast cancer patients, Livagen with cobalt ions reduced DNA single-strand breaks, chromosomal abnormalities and chromatin condensation.
Study details
- Studied
- Lymphocyte cultures from patients with ductal breast cancer
- Main outcome
- DNA single strand breaks, chromosomal abnormalities, sister chromatid exchanges
- Authors' conclusion
- Livagen and cobalt as modifying agents had a protective effect on all studied parameters in lymphocytes of ductal breast cancer patients.
- Limitations
- In vitro lymphocyte study; no numbers given in the abstract.
-
[Functional morphology of an organotypic liver culture exposed to the peptide livagen].Cells / labIn vitro immunocytochemical and morphometric analysis
In organotypic rat liver culture, Livagen stimulated structural and functional markers of hepatocyte regeneration.
Study details
- Studied
- Organotypic liver culture
- Main outcome
- Functional morphology of liver culture
- Authors' conclusion
- The tetrapeptide livagen stimulated structural and functional homeostasis of cell populations in the liver culture, stabilizing morphology and reinforcing regeneration processes.
- Limitations
- In vitro culture study; no quantitative data in the abstract.
-
[Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages].Humans + animals2 weeksIn vitro enzyme assay plus two weeks of oral Livagen in rats
In rats, two weeks of oral Livagen lowered digestive enzyme activity in young animals and raised it in old animals, bringing old-rat values closer to young controls.
Key resultIn vitro, Livagen reduced glycil-L-leucinedipeptidase activity in small intestine by 50%
Study details
- Studied
- Young and old rats; in vitro small-intestine enzyme assays
- Compared with
- Control animals
- Main outcome
- Digestive enzyme activity
- Authors' conclusion
- Livagen is weakly hydrolyzed; after oral administration enzyme activity fell in young rats and rose in old rats, approaching the young control level.
- Limitations
- Animal and in vitro study; numbers per group not stated.
-
[The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology.].No new dataNarrative review
A review of a liver polypeptide complex and the KEDA (Livagen) peptide reports efficacy in animal and in vitro liver-injury models, without clinical trial data.
Study details
- Studied
- Liver polypeptide complex (Ventvil) and KEDA tetrapeptide (Livagen); animal and in vitro models of liver pathology
- Main outcome
- Hepato-, immuno-protective and antiageing effects
- Authors' conclusion
- Ventvil and KEDA peptide normalized immune and antioxidant status and restored liver function in experimental hepatitis, with maximal effects in aging.
- Limitations
- Review of experimental animal and in vitro data.
-
[Genomic instability in atherosclerosis].Cells / labCytogenetic study of cultured lymphocytes with and without Livagen, cobalt ions, or both
In lymphocyte cultures from atherosclerosis patients aged 80+, Livagen alone or with cobalt ions normalised raised chromosomal instability markers (laboratory cell study, no clinical outcome).
Study details
- Studied
- Lymphocyte cultures from patients with atherosclerosis aged 80 years and older, with healthy cultures from the same age group and from 30-35 year-olds as controls
- Compared with
- Lymphocyte cultures of healthy people of two age groups
- Main outcome
- Chromosome aberration, aneuploidy and polyploidy
- Authors' conclusion
- Livagen alone and with cobalt ions was reported to normalise altered genomic indicators in atherosclerosis cells; the authors infer efficacy in prevention of atherosclerosis.
- Limitations
- Cultured cells only; no patient was treated, so the prevention claim is an extrapolation.
-
[Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum].Cells / labIn vitro enzyme assay and radioreceptor binding
Livagen inhibited enkephalin-degrading enzymes in human serum in vitro (IC50 20 microM) but did not bind mu- or delta-opioid receptors in rat brain membranes.
Key resultIC50 of Livagen 20 microM vs 500 microM for Epitalon; no binding to mu- or delta-opioid receptors
Study details
- Studied
- Human serum enzymes and rat brain membrane fractions
- Compared with
- Epitalon; puromycin, leupeptin and D-PAM as reference inhibitors
- Main outcome
- Inhibition of enkephalin hydrolysis; opioid receptor binding
- Authors' conclusion
- Livagen and Epitalon inhibited enkephalin-degrading enzymes from human serum, Livagen more efficiently, without interacting with the opioid receptors tested.
- Limitations
- Biochemical in vitro assay only; no whole-organism or clinical data.
-
[Variability of radiation-induced adaptive response in old age individuals and their correction by Peptide bioregulator -Livagen].Cells / labIn vitro radiation adaptive-response assay with Livagen as a corrective agent
In PHA-stimulated lymphocytes from 72-86 year-old donors, a corrective effect of Livagen on radiation adaptive response was observed (cell study; abstract gives no numbers).
Study details
- Studied
- Cultured lymphocytes from 72-86 year-old and 30-40 year-old people
- Compared with
- Cells of 30-40 year-old individuals
- Main outcome
- Adaptive response to low-dose gamma-rays and copper chloride damage
- Authors' conclusion
- Cells from aged individuals kept the radiation adaptive response, and a corrective activity of Livagen was observed.
- Limitations
- Cultured cells; no quantitative results in the abstract.
-
[Effect of peptide bioregulator and cobalt ions on the activity of NORs and associations of acrocentric chromosomes in lymphocytes of patients with hypertrophic cardiomyopathy and their relatives].Cells / labCytogenetic study with Livagen alone or combined with cobalt ions
In lymphocytes from patients with hypertrophic cardiomyopathy and relatives, Livagen with cobalt ions increased NOR activity and acrocentric chromosome associations, read by the authors as chromatin decondensation (cell study, no clinical outcome).
Study details
- Studied
- Lymphocyte cultures from patients with hypertrophic cardiomyopathy and their relatives
- Main outcome
- Nucleolar organizer region activity; associations of acrocentric chromosomes
- Authors' conclusion
- Authors conclude Livagen and cobalt ions decondense heterochromatinized chromatin in these cells and suggest possible therapeutic relevance.
- Limitations
- Cultured cells; the clinical meaning of the chromosome changes is unproven.
Reported side effects
No clinical trials; the human-derived data are laboratory measurements on cultured cells, so there is no human safety data.
✓ positive · ✗ negative · ~ mixed · ? inconclusive, judged on each paper's own main outcome. Grades: A strong human evidence → D little or none. Papers and verdicts are drawn from PubMed, Europe PMC and Russian journals (CyberLeninka); not medical advice.
Discussions elsewhere
Experiences and questions about Livagen on other sites. Treat anecdotes with care.
Livagen: questions people ask
What is Livagen?
Russian short-peptide bioregulator. One of the Khavinson "bioregulator" peptides from Russian aging research. Evidence comes mainly from Russian cell and animal studies.
How much does Livagen cost?
The cheapest Livagen from an independently tested vendor is $0.475 per mg (Andy Peps Studio, LI20 Livagen 20mg * 10 vials, $95.00). Across 18 listings from 16 vendors the median is $2.45 per mg.
Where can I buy Livagen?
16 vendors tested by Finnrick sell Livagen. The cheapest per mg right now: Andy Peps Studio ($0.475), Baohua Dongnuo Biotechnology BHD ($0.475), LN Peptides ($0.475). 2 of them publish a lab report (COA) for Livagen; compare lab scores and reports in the table above before buying.
How much bacteriostatic water for 20 mg of Livagen?
Adding 2 mL of bacteriostatic water to a 20 mg vial of Livagen gives 10 mg/mL: each 10 units on a U-100 insulin syringe holds 1,000 mcg. With 1 mL it's 20 mg/mL (2,000 mcg per 10 units); with 3 mL, 6.667 mg/mL (666.7 mcg per 10 units). More water makes small amounts easier to measure. Mixing charts: 20 mg.
Is Livagen FDA approved?
Sold as a supplement in Russia; not approved in the US. Research use only.
Can Livagen be compounded in the US?
Not an FDA-approved drug and not nominated for FDA's 503A bulks list, so US pharmacies can't legally compound it. Compounding status for every peptide.
Does Livagen work? What does the research say?
Evidence grade D (little or no evidence), from 12 papers: Almost entirely cell studies (cultured lymphocytes, liver tissue) with a single rat study; no clinical outcomes in people or animals. Livagen (the tetrapeptide Lys-Glu-Asp-Ala) has been studied mainly by Russian and Georgian groups in cultured lymphocytes from elderly people and patients, where it decondenses chromatin and reactivates ribosomal genes, plus some rat liver and enzyme work. These are laboratory measurements on cells rather than clinical trials, and no study reports a health outcome in people. See the papers.
What dose of Livagen was used in studies?
Livagen is tested only in animals or cells. Studies used cultured lymphocytes from elderly people, rat liver and pancreas tissue cultures, and rats given Livagen by mouth for two weeks; none of the abstracts state the concentration or mg/kg dose. These are amounts used in published studies or official labels, not a recommendation.